Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 102

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug Development

Josh Lipson, PhD & Roman Palitsky, MDiv, PhD: Psychedelic Harms and the Post-Psychedelic Challenges Study

Why Perimenopause Belongs in Psychedelic Research

FILAMENT HEALTH TO SUPPLY PSILOCYBIN FOR RECIPIENTS OF THE CANADIAN INSTITUTES...

COMPASS Pathways Secures Term Loan Facility for Up to $50 Million...

Small Pharma Announces SPL028 R&D Strategy Update

Wesana Health Announces Closing of Previously Announced SANA-013 Asset Sale

Into the Psychedelic Practitioner Toolbox: Using a Transpersonal Approach

PT420 – DanceSafe: Drug Testing, Fentanyl Myths, and the Importance of...

Psychedelic Summer Safety: The Ultimate Guide to Making the Most Out...

Psychedelics Weekly – A Recap of Psychedelic Science 2023

Psychedelic Bulletin #140: Regulators Weigh in on Psychedelics; Psychedelic Biotech Strikes...

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC.

Load more

EDITOR PICKS

Credentials, Clinics, and Costs: Stakeholders Respond to HRSA’s Psychedelic Therapy RFI

Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Paving the Way: Husseini Manji on Spravato’s Lessons for Psychedelic Drug...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©